Poly Medicure's Q4 profit drops 29% as acquisition costs bite
Consolidated net profit fell 29% in Q4, with standalone down 7%. The results confirm softer trends already flagged in an earlier concall.
— 3 earlier stories on Poly Medicure Ltd. →What's new
- Poly Medicure's Q4 consolidated net profit fell ~29% YoY, partly due to acquisition-related costs.
- Standalone Q4 net profit declined ~7% YoY.
- Board approved a dividend and routine auditor reappointments alongside the results.
Why this matters
The results are not a surprise. The market already knew about the revenue baseline cut for PendraCare and the reduced renal growth target from a prior concall. This filing simply confirms the financial impact of those known headwinds, offering no new model revision triggers.
What we're watching
- The pace at which acquisition-related costs normalize in coming quarters.
- Any update on the execution against the revised renal growth target.
- The dividend payout ratio relative to the lower profit base.
The full read
Poly Medicure's Q4 consolidated net profit fell 29% year-on-year, a decline partly driven by acquisition-related costs. Standalone profit dropped 7%. The numbers land without shock because the company had already told investors in a concall that its PendraCare revenue baseline was cut and its renal growth target was reduced. This filing confirms the profit impact of those known headwinds. For investors, the incremental value is in seeing the cost profile play out in audited accounts. The dividend recommendation and auditor reappointments are routine. The open question is whether acquisition costs fade in the next two quarters, or stick around.
Questions answered
- Why did Poly Medicure's consolidated profit drop more sharply than standalone?
- The filing attributes the steeper consolidated profit decline partly to acquisition-related costs. Standalone profit fell 7% while consolidated fell 29%, indicating the drag is heavier in the merged entity.
- Were these results expected?
- Yes. The prior concall summary had already disclosed the PendraCare revenue baseline cut and the renal growth target reduction. These audited numbers confirm the financial impact of those previously announced challenges.
- What else did the board decide?
- Alongside approving the Q4 and FY2026 financials, the board recommended a dividend and approved the reappointment of statutory auditors. The dividend is a routine annual action.
Poly Medicure Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on POLYMED →- 25 May 2026 · 7:58 PM IST Poly Medicure's Q4 profit drops 29% as acquisition costs bite
- 46d ago Poly Medicure walks back PendraCare revenue, renal growth targets
- 46d ago Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs
- 46d ago Poly Medicure profit slips in Q4, hit by acquisition costs